Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 2/20 | 0.48 |
| ▸ | DNM2 | P50570 | 2/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CCR4 | P51679 | 4/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516259 | 0.90 | CYP1A2 (0.45) | HRH4MERTKDNM2CCR4PDPK1 | |
| SCHEMBL12280402 | 0.83 | DYRK1B (0.46) | HRH4DNM2CCR4PDPK1 | |
| SCHEMBL28860465 | 0.83 | MKNK1 (0.42) | CCR4PDPK1 | |
| SCHEMBL28020340 | 0.82 | MKNK1 (0.50) | CCR4PDPK1 | |
| SCHEMBL8439579 | 0.80 | GBA1 (0.46) | DNM2TLR8GBA1 | |
| SCHEMBL19788436 | 0.79 | PDPK1 (0.48) | HRH4DNM2CCR4PDPK1 | |
| SCHEMBL10055017 | 0.78 | CLK4 (0.52) | — | |
| SCHEMBL19477219 | 0.78 | DNM2 (0.71) | HRH4MERTKDNM2TLR8MAPK8 | |
| SCHEMBL13403107 | 0.78 | HRH4 (0.56) | HRH4MERTKDNM2TLR8MAPK8 | |
| SCHEMBL14619914 | 0.77 | HRH4 (0.55) | HRH4MERTKDNM2TLR8MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | YALE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-7205410-B2 | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346951-A1 | MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS | ASGR1, MSR1, LDLR | HRH4 3145/4885MERTK 1284/4885DNM2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.